Will RVMD's cash and investments (excluding Royalty Pharma draws) fall below $1.0B by June 30, 2026?

Starting from $2.03B, two quarters of burn at the Q4 2025 rate (~$300-330M cash burn after removing SBC) would leave approximately $1.37-1.43B. To reach below $1.0B in two quarters would require ~$515M+ per quarter in cash consumption — nearly 60% above Q4 2025 levels. This would require a massive acceleration in spending that contradicts management guidance and execution patterns. Interest income of ~$20-25M/quarter provides additional offset. The math makes this very unlikely.

The question specifies 'excluding Royalty Pharma draws,' isolating organic cash. Q4 2025 net loss was $364.9M but included ~$34M noncash SBC, so cash burn was ~$330M. Even adding 10-15% quarterly acceleration for FY2026 ramp-up, cash burn would be ~$360-380M per quarter. Two quarters: ~$720-760M burn. $2.03B - $760M = $1.27B, still well above $1.0B. Would need ~80% acceleration from Q4 2025 to breach $1.0B. Not realistic in two quarters.

There is a scenario where this could happen: if RVMD accelerates clinical and commercial spending dramatically in Q1-Q2 2026 ahead of RASolute 302 readout, and simultaneously faces unexpected costs (manufacturing ramp, CRO overruns, lawsuit settlements). However, this would require spending far above the annualized $1.6-1.7B guidance rate in just the first half. Companies rarely front-load this aggressively. Assigning 15% to account for the possibility of unexpected large outlays.

Simple arithmetic: $2.03B - (2 × ~$330M) = ~$1.37B. Even at the high-end guided quarterly rate ($425M including SBC), cash OpEx is ~$375M/quarter. Two quarters: $750M. $2.03B - $750M + ~$45M interest income = ~$1.33B. Below $1.0B requires catastrophic acceleration that contradicts all available guidance and patterns.

The only path below $1.0B by Q2 would be a massive one-time outlay — such as a large acquisition, legal settlement, or upfront manufacturing commitment. RVMD's disclosure history doesn't suggest any such event is likely. Clinical trial costs scale gradually, not in step functions. Probability under 10%.

Slightly above 10% to account for unknown unknowns — a major investment (manufacturing facility, large CRO commitment, or strategic transaction) could consume significant cash. But even a $300M one-time event would only bring the total to ~$1.05B, barely below the threshold. The probability is low but not negligible if we consider extreme scenarios.

Math is clear: $2.03B minus two quarters of ~$330M burn = ~$1.37B. Well above $1.0B. Very unlikely to breach.

Would require nearly doubling the quarterly burn rate in both Q1 and Q2 2026. No precedent or indication of this level of acceleration. Under 10%.

Starting with $2.03B and burning at guided rates leaves ample buffer above $1.0B. Only catastrophic spending surprise would breach threshold. Very low probability.